A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study.

Abstract

OBJECTIVE:

To evaluate the effectiveness and toxicity of mifepristone in patients with ovarian, peritoneal and fallopian tube cancers.

METHODS:

Patients with confirmed epithelial ovarian, peritoneal and fallopian tube cancers which were persistent or recurred in less then 1 year after primary chemotherapy were entered into this study. Patients were given mifepristone 200 mg by mouth daily for a 28 day cycle. The medication was stopped for unacceptable toxicity or tumor progression.

RESULTS:

Twenty-four patients were entered into the study. Twenty-two patients were evaluable for response. Only one patient had a partial response for a response rate of only 4.5% (90% confidence interval: 0.2%, 19.8%).

CONCLUSION:

Mifepristone has not proven to be an effective agent in the treatment of patients with recurrent or persistent ovarian, peritoneal and fallopian tube cancers.

• Authors: Thomas F Rocereto, William E Brady, Mark S Shahin, James S Hoffman, Laurie Small, Jacob Rotmensch, Robert S Mannel
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 116 Issue 3 Pg. 332-4 (Mar 2010) ISSN: 1095-6859 [Electronic] United States
• PMID: 19922989 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Mifepristone

Topics

• Administration, Oral
• Adult
• Aged
• Aged, 80 and over
• Disease-Free Survival
• Fallopian Tube Neoplasms (drug therapy)
• Female
• Humans
• Kaplan-Meier Estimate
• Middle Aged
• Mifepristone (adverse effects, therapeutic use)
• Neoplasm Recurrence, Local (drug therapy)
• Ovarian Neoplasms (drug therapy)
• Peritoneal Neoplasms (drug therapy)